Beneath the undulating and unpredictable waves of a turbulent economy and new tariff realities, a sort of calm has settled over the pharmaceutical industry. The message from CEOs? Don’t worry — we’ve got this.
The world’s largest drugmakers aren’t quite out of the woods, of course, but as they reported earnings for the first quarter, they looked back on a period of U.S. executive orders and shifting trade policies as chaotic, but manageable.
A common thread among pharma leaders was that they don’t want to overreact to an uncertain future by avoiding a rogue wave and steering into a cliff face. But each company also entered 2025 with its own set of priorities and challenges, shaping R&D and commercial enterprises despite the shifting winds above.
Here’s what Big Pharma CEOs have said in recent weeks about where they stand in the face of macroeconomic trends and…